Nu­mero quat­tro: Im­munol­o­gy ex­perts at deal-fo­cused IFM line up $55.5M for the next leg of their drug ex­plo­ration jour­ney

It’s pipeline prim­ing time at IFM Ther­a­peu­tics. And they have the mon­ey to get the job done.

The im­munol­o­gy ex­perts at the dis­cov­ery out­fit have lined up $55.5 mil­lion in new ven­ture back­ing from an ex­pand­ed syn­di­cate — still in­clud­ing their big be­liev­ers at At­las. And it’s not hard to fig­ure out the mo­ti­va­tion.

Gary Glick, who’s mov­ing from CEO to ex­ec­u­tive chair­man on this round, and his team have lined up a slate of deals for their ear­ly-stage work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.